BIOFILCHEM2024-07-012024-09-30 BIOFILCHEM2024-07-012024-09-30 BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneOperatingExpenses03Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourOperatingExpenses03Member BIOFILCHEM2024-09-30 BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member BIOFILCHEM2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member BIOFILCHEM2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524396 BIOFILCHEM NOTLISTED Biofil Chemicals & Pharmaceuticals Limited Equity 2024-04-01 2025-03-31 2024-11-14 2024-11-07 INR Lakhs Half yearly 17:00:00 19:05:00 2024-11-14 2024-11-14 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Standalone 24126000.00 162000.00 24288000.00 4216000.00 54011000.00 -38534000.00 1829000.00 90000.00 987000.00 1361000.00 23960000.00 328000.00 0.00 328000.00 84000.00 0.00 84000.00 0.00 244000.00 0.00 0.00 0.00 0.00 244000.00 0.00 244000.00 0.00 0.00 162738000.00 10 0.01 0.01 0.00 0.00 0.01 0.01 1. The above Unaudited financial results of the company for the 2nd quarter and half year ended 30th September 2024 have been reviewed by the Audit committee and subsequently approved by the Board of Directors in their meeting held on Thursday, 14th Day of November 2024. The above results for the 2nd quarter and half year ended 30th September, 2024 have been reviewed by the statutory auditors of the company in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 who have expressed an unmodified opinion. The company’s management has exercised necessary due diligence to ensure that the unaudited financial result provide a true and fair view of its affairs. 2. The Statement of Assets & Liabilities as at September 30, 2024 is annexed with the financial results along with the Cash Flow Statements. 3. This above unaudited Financial Results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (SEBI) and the Companies (Indian Accounting Standards) Rules, 2015 (Ind-AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. 4. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments a. Pharma Product b. Chemicals Division 5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. 6. The aforesaid un-Audited financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors. Multi segment 2024-04-01 2024-09-30 Unaudited Standalone 108560000.00 455000.00 109015000.00 11078000.00 128312000.00 -42543000.00 3215000.00 197000.00 1975000.00 4173000.00 106407000.00 2608000.00 0.00 2608000.00 671000.00 0.00 671000.00 0.00 1937000.00 0.00 0.00 0.00 0.00 1937000.00 0.00 1937000.00 0.00 0.00 162738000.00 10 0.12 0.12 0.00 0.00 0.12 0.12 Administrative Expenses 441000.00 Manufacturing Expenses 801000.00 Selling and Distribution Expenses 119000.00 Administrative Expenses 1605000.00 Manufacturing Expenses 1993000.00 Selling and Distribution Expenses 575000.00 84268000.00 0.00 0.00 0.00 0.00 0.00 84268000.00 68040000.00 0.00 255113000.00 1568000.00 634000.00 0.00 257315000.00 10778000.00 336133000.00 420401000.00 162738000.00 21227000.00 183965000.00 183965000.00 0.00 0.00 0.00 3554000.00 3554000.00 4551000.00 227046000.00 231597000.00 614000.00 671000.00 232882000.00 236436000.00 420401000.00 Chemicals Division 5906000.00 Pharma Unit 18220000.00 Chemicals Division 16376000.00 Pharma Unit 92184000.00 24126000.00 108560000.00 24126000.00 108560000.00 Chemicals Division 1120000.00 Pharma Unit -702000.00 Chemicals Division 3291000.00 Pharma Unit -506000.00 418000.00 2785000.00 90000.00 181000.00 0.00 -4000.00 328000.00 2608000.00 Chemicals Division 211128000.00 Pharma Unit 199449000.00 410577000.00 Chemicals Division 86855000.00 Pharma Unit 142205000.00 229060000.00 197000.00 -42543000.00 75178000.00 0.00 -5327000.00 0.00 0.00 0.00 0.00 -48502000.00 0.00 -2293000.00 0.00 1975000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -21315000.00 -18707000.00 0.00 0.00 0.00 1892000.00 0.00 -20599000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 162000.00 0.00 0.00 0.00 0.00 197000.00 0.00 0.00 -35000.00 -20634000.00 0.00 -20634000.00 22835000.00 2201000.00 0.00 0.00 0.00 0.00